Home › Companies › KYMERA THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 25, 2025: 4 items on KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025: 2 approved · 2 passed (calculated).
Notable dissent: 1 director (12.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Albers, J.D., MBA | 55,765,189 | -- | -- | 3,142,251 | 2,748,381 | 95% | Passed (calculated) | — |
| Elect Director: Felix J. Baker, Ph.D. | 51,745,887 | -- | -- | 7,161,553 | 2,748,381 | 88% | Passed (calculated) | — |
| 2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers | 54,364,880 | 4,531,413 | 11,147 | -- | 2,748,381 | 92% | Approved | — |
| 3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 61,644,725 | 4,768 | 6,328 | -- | 0 | 99.9% | Approved | — |
Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
193 asset managers disclosed a vote on at least one KYMERA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Felix J. Baker, Ph.D.
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 51,745,887 for, 7,161,553 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 20,153,415 for, 1,280,898 withheld, 1,284,444 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,060,220 | 0 | 0 | 17,284 | For |
| BlackRock | 0 | 0 | 1,168,188 | 0 | Abstain |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 447,732 | Withhold |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 274,195 | 0 | 0 | 4,494 | For |
| State Street | 726 | 0 | 0 | 248,648 | Withhold |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 19,144 | 0 | 0 | 120,330 | Mixed |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 79,262 | Withhold |
| Pacific Life | 0 | 0 | 0 | 70,539 | Withhold |
| John Hancock | 49,943 | 0 | 16,839 | 0 | Mixed |
| Lincoln Financial | 0 | 0 | 0 | 65,919 | Withhold |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 52,004 | 0 | Abstain |
| Brighthouse | 47,057 | 0 | 0 | 1 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 839 | 0 | 0 | 39,981 | Withhold |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Jeffrey Albers, J.D., MBA
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Albers, J.D., MBA”): 55,765,189 for, 3,142,251 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 21,809,989 for, 854,124 withheld, 54,644 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 447,732 | Withhold |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 274,195 | 0 | 0 | 4,494 | For |
| State Street | 249,054 | 0 | 0 | 320 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 94,484 | 0 | 0 | 44,990 | Mixed |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 79,262 | Withhold |
| Pacific Life | 14,635 | 0 | 0 | 55,904 | Mixed |
| John Hancock | 49,943 | 0 | 16,839 | 0 | Mixed |
| Lincoln Financial | 34,700 | 0 | 0 | 31,219 | Mixed |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Brighthouse | 47,057 | 0 | 0 | 1 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 839 | 0 | 0 | 39,981 | Withhold |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
92% Approved · of votes cast
Prior year: 97.1% for (June 18, 2024 meeting) ▼ 4.8 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers; and
KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,364,880 for, 4,531,413 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,370 | 405 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,033,782 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 447,732 | 0 | 0 | Against |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,284 | 277,405 | 0 | 0 | Against |
| State Street | 249,374 | 0 | 0 | 0 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 139,474 | 0 | 0 | 0 | For |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 79,262 | 0 | 0 | 0 | For |
| Pacific Life | 14,635 | 55,904 | 0 | 0 | Mixed |
| John Hancock | 66,782 | 0 | 0 | 0 | For |
| Lincoln Financial | 64,444 | 1,475 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Brighthouse | 47,058 | 0 | 0 | 0 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 40,820 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 0 | 28,302 | 0 | 0 | Against |
| AIG/SunAmerica | 26,969 | 0 | 0 | 0 | For |
Fund voting reports, all 65 managers: 20,716,357 for, 1,932,752 against, 5,794 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 6,564,519 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,995,929 | 0 | 0 | 0 | For |
| Wellington | 5,390,449 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 4,896,462 | 0 | 0 | 0 | For |
| BVF INC/IL | 4,607,955 | 0 | 0 | 0 | For |
| Fidelity | 4,104,292 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,829,980 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,791,209 | 0 | 0 | 0 | For |
| BlackRock | 1,487,750 | 94 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,101,087 | 0 | 0 | 0 | For |
| State Street | 1,088,549 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,033,782 | 0 | 0 | Against |
| Redmile Group, LLC | 0 | 983,413 | 0 | 0 | Against |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 593,000 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 503,636 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 464,449 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 418,727 | 0 | 0 | Against |
| BRAIDWELL LP | 392,764 | 0 | 0 | 0 | For |
| Charles Schwab | 386,952 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 263,673 | 0 | 0 | 0 | For |
| Northern Trust | 226,246 | 0 | 0 | 0 | For |
| UBS | 0 | 197,956 | 0 | 0 | Against |
| Janus Henderson | 149,214 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 146,332 | 0 | 0 | 0 | For |
| Vanguard | 139,048 | 0 | 0 | 0 | For |
Institutional-manager reports, all 146 managers: 44,375,000 for, 3,783,974 against. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 18, 2024 meeting) unchanged
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 61,644,725 for, 4,768 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 22,712,699 for, 264 against, 5,794 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 447,732 | 0 | 0 | 0 | For |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 278,689 | 0 | 0 | 0 | For |
| State Street | 249,374 | 0 | 0 | 0 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 139,474 | 0 | 0 | 0 | For |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 79,262 | 0 | 0 | 0 | For |
| Pacific Life | 70,539 | 0 | 0 | 0 | For |
| John Hancock | 66,782 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,919 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Brighthouse | 47,058 | 0 | 0 | 0 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 40,820 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 65,112,714 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 14.04% |
| 2 | T. Rowe Price | 7.61% |
| 3 | Fidelity | 4.73% |
| 4 | BlackRock | 1.79% |
| 5 | Capital Group | 1.59% |
| 6 | MUTUAL FUND SERIES TRUST | 0.81% |
| 7 | MFS | 0.69% |
| 8 | Charles Schwab | 0.59% |
| 9 | Prudential/PGIM | 0.43% |
| 10 | State Street | 0.38% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 10.08% |
| 2 | BAKER BROS. ADVISORS LP | 9.21% |
| 3 | Wellington | 8.28% |
| 4 | Atlas Venture Life Science Advisors, LLC | 7.52% |
| 5 | BVF INC/IL | 7.08% |
| 6 | Fidelity | 6.30% |
| 7 | Siren, L.L.C. | 4.35% |
| 8 | Avoro Capital Advisors LLC | 4.29% |
| 9 | BlackRock | 2.29% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Avoro Capital Advisors LLC | 6,727,263 | 10.33% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| T. Rowe Price | 6,702,450 | 10.29% | Form 13F, quarter ended March 31, 2025 |
| Entities affiliated with BVF Partners L.P. | 6,526,900 | 10.02% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Entities affiliated with Baker Bros. Advisors LP | 6,008,373 | 9.23% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Felix Baker, Ph.D. | 6,008,373 | 9.23% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| T. Rowe Price Investment Management, Inc. | 5,460,257 | 8.39% | Schedule 13G, filed May 15, 2026 |
| Wellington Management Group LLP | 5,307,326 | 8.15% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| BVF PARTNERS L P/IL | 5,237,151 | 8.04% | Schedule 13D, filed June 26, 2026 |
| Vanguard Group | 5,231,392 | 8.03% | Form 13F, quarter ended March 31, 2025 |
| FMR LLC | 5,109,141 | 7.85% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
Percentages above are of 65,112,714 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At KYMERA THERAPEUTICS INC.'s shareholder meeting held June 25, 2025, in the 2024-2025 proxy season, 193 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,039 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — KYMERA THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “KYMERA THERAPEUTICS (KYMR) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/kymera-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.